Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00335738 · ClinicalTrials.gov registry record · Phase 3
Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma
A Phase 3 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 331
- Enrollment target
NCT00335738 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 331 participants.
The verdict
NCT00335738, a Phase 3 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 331 participants
- Enrollment target
Study Summary
This phase III trial is studying vincristine, carboplatin, and etoposide to see how well they work compared to observation only in treating patients who have undergone surgery for newly diagnosed retinoblastoma. Drugs used in chemotherapy, such as vincristine, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, no additional treatment is needed for the tumor until it progresses. In this case, observation may be sufficient.
Interventions
- DRUG carboplatin
- DRUG etoposide
- DRUG liposomal vincristine sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 331 participants |
| Start Date | 2005-12 |
| Est. Completion | 2020-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00335738
The ClinicalTrials.gov registry entry for NCT00335738 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 331 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00335738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00335738 about?
NCT00335738 is a clinical study titled "Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma". This phase III trial is studying vincristine, carboplatin, and etoposide to see how well they work compared to observation only in treating patients who have undergone surgery for newly diagnosed retinoblastoma. Drugs used in chemotherapy, such as vincristine, carboplatin, and etoposide, work in dif...
What is the current status of trial NCT00335738?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 331 participants. The study started on 2005-12. Estimated completion is 2020-09-30.
What interventions are being tested in trial NCT00335738?
The interventions under investigation include: carboplatin (DRUG), etoposide (DRUG), liposomal vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT00335738?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.